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Circulation 2012;126:1752–69.ReplyCatheter Ablation to Treat
Sustained Ventricular
Tachycardia in Patients With
Chagas Cardiomyopathy and
Implantable Cardioverter-DeﬁbrillatorWe would like to thank Drs. Scanavacca and Sosa for their letter
regarding our review (1), which outlined an important aspect
related to the management of patients with Chagas heart disease
(CHD) and malignant arrhythmias. Patients with CHD have a
higher risk of death than idiopathic dilated cardiomyopathy (2),
possibly related to the higher frequency and severity of ventricular
arrhythmia in CHD subjects when compared with other structural
heart diseases (3,4). The higher number of shocks observed in
CHD patients is related to the higher incidence of ventricular
tachycardia (VT) and ﬁbrillation in implantable cardioverter-
deﬁbrillator (ICD) patients (4) and to the higher risk of death (5).
Amiodarone, which has been largely used in CHD (6), in association
with beta-blockers, may prevent shocks in ICD patients but not in
all patients, and only at the cost of an increased risk of drug-related
adverse effects (7). As Dr. Scanavacca and Dr. Sosa correctly
point out, ablation therapy emerges as the ﬁrst-line treatment for
those receiving frequent ICD therapies due to incessant and recur-
rent VT in spite of amiodarone and beta-blocker therapy in CHD.However, several aspects of this treatment option in CHD
should be better elucidated. Dr. Scanavacca and Dr. Sosa’s group
have to be praised for the introduction of the technique of
nonsurgical transthoracic epicardial catheter ablation to treat
recurrent VT in CHD patients (8), which is now used for VT
ablation of other etiologies (9). CHD patients frequently have
epicardial VT breakthroughs (8,10) and a combined epicardial/
endocardial substrate mapping, and ablation has been proposed as a
ﬁrst-line therapy for preventing VT recurrences and appropriate
ICD therapies (8,10). Indeed, the use of extended substrate
modiﬁcation in patients with ischemic cardiomyopathydwith
routine approach to endocardial and epicardial surfacedwas more
effective in preventing VT recurrences than the limited (traditional)
substrate ablation (9). This is a hypothesis that deserves to be tested
in CHD in a prospective, randomized trial.
CHD is now a global health problem, but most infected patients
are poor people born in rural, endemic areas in Latin America;
thus, few randomized studies have been performed for treatment of
CHD complications (11,12). Globalization of knowledge and
evidence-based medicine should be matched by attempts to provide
solutions for regional and neglected pathologies in addition to
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